FDA Panel Favors Genzyme’s Myozyme


An FDA panel voted Tuesday in favor of recommending conditional approval of a new version of Cambridge biotech firm Genzyme’s (NASDAQ:GENZ) drug alglucosidase alfa (Myozyme) for Pompe disease, according to a report by Bloomberg News. Though the panel’s nod does not guarantee approval of the drug, it puts Genzyme one step closer to marketing a version of alglucosidase alfa made in larger batches than its approved version made in smaller containers.

By posting a comment, you agree to our terms and conditions.